(Q44583724)

4 December 2017

title

A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy (English)

1 reference

4 December 2017

1 reference

1 reference

1 reference

6

Ian A Wilson

1 reference

4 December 2017

1

Christoph Rader

1 reference

4 December 2017

James M Turner

2

1 reference

4 December 2017

Andreas Heine

3

1 reference

4 December 2017

Doron Shabat

4

1 reference

4 December 2017

Subhash C Sinha

5

1 reference

4 December 2017

Richard A Lerner

7

1 reference

4 December 2017

Carlos F Barbas

8

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

Journal of Molecular Biology

4 December 2017

published in

1 reference

4 December 2017

volume

332

1 reference

4 December 2017

issue

4

1 reference

4 December 2017

page(s)

889-899

1 reference

Reactive immunization: a unique approach to catalytic antibodies

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Immune versus natural selection: antibody aldolases with enzymic rates but broader scope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Broadening the Aldolase Catalytic Antibody Repertoire by Combining Reactive Immunization and Transition State Theory: New Enantio- and Diastereoselectivities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Using antibody catalysis to study the outcome of multiple evolutionary trials of a chemical task

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Multiple event activation of a generic prodrug trigger by antibody catalysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Antibody-directed enzyme prodrug therapy (ADEPT): a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Antibody libraries in drug and target discovery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Humanization of an anti-p185HER2 antibody for human cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Improving the efficacy of antibody-based cancer therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Analysis of heavy and light chain pairings indicates that receptor editing shapes the human antibody repertoire

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Antibody arrays for high-throughput screening of antibody-antigen interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Humanization of murine monoclonal antibodies through variable domain resurfacing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Integrin alpha(v)beta3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Aldol sensors for the rapid generation of tunable fluorescence by antibody catalysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Design of selectively activated anticancer prodrugs: elimination and cyclization strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Replacing the complementarity-determining regions in a human antibody with those from a mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Phage display of a catalytic antibody to optimize affinity for transition-state analog binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Reconstructing Aldolase Antibodies to Alter Their Substrate Specificity and Turnover

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Development of a genetic selection for catalytic antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Design and production of novel tetravalent bispecific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Phage display selection of peptides possessing aldolase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

An efficient benchtop system for multigram-scale kinetic resolutions using aldolase antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Modification of an ELISA-based procedure for affinity determination: correction necessary for use with bivalent antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

Influence of solid-phase antigen in competition enzyme-linked immunosorbent assays (ELISAs) on calculated antigen-antibody dissociation constants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2803%2900992-6

10.1016/S0022-2836(03)00992-6

7 January 2021

Identifiers

DOI

1 reference

4 December 2017

1 reference